The Japanese laboratory Eisai and its American partner Biogen have just presented the results of a treatment trial at the international congress of the Alzheimer’s disease which was held in Chicago a few days ago. This treatment targets the amyloid protein, “the famous protein that is deposited in the brain of patients” Explain on France Inter Professor Bruno Dubois, head of the cognitive diseases department at Pitié Salpêtrière, who attended this congress.
This new treatment has been tested on 854 people with a mild form or early of Alzheimer’s disease. The results showed that patients who received the highest dose of this drug (a monoclonal antibody called Ban 2401) or 10mg per kilogram of weight, twice a month intravenously, showed large reductions in amyloid plaques in their brains. .
“They had about 93% less beta-amyloid compared to people on a placebo” do we learn on WebMD. These patients also performed better on a test called ADAS-cog, a set of 11 complete tasks that measure deficits in memory, language, attention and other mental abilities.
Dr. Lynn Kramer, chief clinical officer of Eisai Pharmaceuticals, said the company will present this data to the FDA to discuss next steps. But he did not commit to a date for the phase 3 trial. “We need more data, more time.”